Want to see RXRX full AI Analyst Report?
RXRX Stock Chart & Stats
$3.78
-$0.34(-4.54%)
At close: 4:00 PM EST
$3.78
-$0.34(-4.54%)
Day’s Range― - ―
52-Week Range$2.77 - $7.18
Previous CloseN/A
Volume5.68M
Average Volume (3M)22.77M
Market Cap
$2.10B
Enterprise Value$808.67M
Total Cash (Recent Filing)$654.47M
Total Debt (Recent Filing)$72.38M
Price to Earnings (P/E)―
Beta3.24
Next Earnings
Aug 11, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding524,677,860
10 Day Avg. Volume23,738,964
30 Day Avg. Volume22,768,700
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue12.20
Enterprise Value/Gross Profit-35.42
Enterprise Value/Ebitda-1.69
Forecast
1Y Price Target
$7.38Price Target Upside95.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$61.30M
Bulls Say, Bears Say
Bulls Say
Platform Scale & Proprietary DataRecursion's unusually large proprietary dataset and multiple high-dimensional biology maps create a durable competitive moat for its AI-native discovery engine. Persistent, hard-to-replicate data improves model accuracy, supports target ID and patient stratification, and raises barriers to entry for competitors and new entrants.
Partnership Traction And Milestone InflowsOver $500M in partner inflows and multiple delivered milestones demonstrate external validation and recurring non-dilutive funding. Deep collaborations reduce financing pressure, accelerate program advancement via partner resources, and signal commercial demand for the platform beyond internal pipeline success.
Balance Sheet Runway And Cost DisciplineWith $665M cash, explicit runway into early 2028, and a sustained ~30% reduction in operating expenses plus < $390M 2026 opex guidance, management has extended financial flexibility. This provides time to reach key clinical readouts and partner decisions before needing material new financing, improving execution optionality.
Bears Say
Persistent Negative Cash GenerationRecurring negative operating and free cash flow (~-$321M TTM) indicates ongoing heavy cash burn. Over 2-6 months this structural drain makes progress contingent on partner payments or capital markets access; delays in milestones or readouts could force dilutive financing or slow program timelines.
Negative Gross Profit And Weak ProfitabilityNegative gross profit in recent periods and extremely wide negative net margins show the business has not reached scalable unit economics. Structural negative gross margins undermine the pathway to sustainable operating leverage and make long-term profitability reliant on successful commercialization or materially improved cost structure.
Regulatory And Clinical Uncertainty For First-in-disease ProgramsREC-4881's first-in-disease status creates structural regulatory uncertainty: lack of precedent means pivotal endpoints, population selection and trial design remain unsettled. Such ambiguity can extend timelines, increase trial size or complexity, and raise development costs, affecting commercialization probability and cash runway.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals, Inc’s price range in the past 12 months?
Recursion Pharmaceuticals, Inc lowest stock price was $2.77 and its highest was $7.18 in the past 12 months.
What is Recursion Pharmaceuticals, Inc’s market cap?
Recursion Pharmaceuticals, Inc’s market cap is $2.10B.
When is Recursion Pharmaceuticals, Inc’s upcoming earnings report date?
Recursion Pharmaceuticals, Inc’s upcoming earnings report date is Aug 11, 2026 which is in 33 days.
How were Recursion Pharmaceuticals, Inc’s earnings last quarter?
Recursion Pharmaceuticals, Inc released its earnings results on May 06, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.045.
Is Recursion Pharmaceuticals, Inc overvalued?
According to Wall Street analysts Recursion Pharmaceuticals, Inc’s price is currently Undervalued.
Does Recursion Pharmaceuticals, Inc pay dividends?
Recursion Pharmaceuticals, Inc does not currently pay dividends.
What is Recursion Pharmaceuticals, Inc’s EPS estimate?
Recursion Pharmaceuticals, Inc’s EPS estimate is -0.24.
How many shares outstanding does Recursion Pharmaceuticals, Inc have?
Recursion Pharmaceuticals, Inc has 524,677,860 shares outstanding.
What happened to Recursion Pharmaceuticals, Inc’s price movement after its last earnings report?
Recursion Pharmaceuticals, Inc reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went up 1.78%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals, Inc?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.38 (95.11% Upside)
$7.38 (95.11% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.10%
12-Months-Change
Fundamentals
Return on Equity
-54.32%
Trailing 12-Months
Asset Growth
2.63%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals, Inc
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple clear positives: a clinical proof of concept (REC-4881), encouraging early clinical safety/PK/PD for REC-1245, first patient dosed for REC-4539, strong partnership traction (> $500M inflows, 10 milestones), platform efficiency gains (≈90% fewer compounds, ~2x faster candidate progression), and a 30% YoY reduction in cash operating expenses with $665M cash (runway into early 2028). The primary negatives are that the programs are still early (key readouts and registrational plans pending), regulatory uncertainty for first-in-disease indications, potential safety risks as dose escalation continues, and a finite runway that could be pressured by delays. Overall, the highlights materially outweigh the lowlights given the combination of clinical proofs, platform progress, partnership milestones, and cost discipline.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$7.38
▲(95.11% Upside)
Technical Analysis
Ownership Overview
2.99% Insiders
12.97% Mutual Funds
0.05% Other Institutional Investors
56.48% Public Companies and Individual Investors